Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study

Summary

The purpose of this study is to investigate if an angiotensin II receptor blocker, valsartan 160 mg/day is more effective to reduce the incidence of cardiovascular events as compared to 40 mg/day in patients with moderate renal dysfunction.

Timeline

Start

2006-08

Primary completion

2015-03

Completion

2015-03

Drugs

Indications